A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

DOI: 10.1016/s0167-8140(97)00220-x
Radiotherapy and Oncology, 1998, 46, 135-46.

#	Paper	IF	Citations
496	Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. *Radiotherapy and Oncology*, **1998**, 48, 115-22	5.3	97
495	Comment on: Conservative surgery and radiotherapy in early stage breast cancer: a comparison between tumourectomy and quadrantectomy. *Radiotherapy and Oncology*, **1998**, 48, 346-7	5.3	
494	An external marker for accurate patient positioning in radiotherapy CT scanning. *Radiotherapy and Oncology*, **1998**, 48, 343-4	5.3	1
493	Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85. *Radiotherapy and Oncology*, **1998**, 48, 344-6	5.3	2
492	Correspondence. *Radiotherapy and Oncology*, **1998**, 48, 345-346	5.3	
491	Radiotherapy in Scandinavia. *Acta Oncologica*, **1998**, 37, 553-60	3.2	4
490	Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide. *Acta Oncologica*, **1999**, 38, 875-82	3.2	27
489	Inducible repair and the two forms of tumour hypoxia--time for a paradigm shift. *Acta Oncologica*, **1999**, 38, 903-18	3.2	63
488	[Meta-analysis of clinical studies: value for the wise or risk for harm?]. **1999**, 94 Suppl 2, 17-20		0
487	Tumoroxygenierung und Hypoxie. **1999**, 5, 1000-1007		5
486	Role of short TE 1H-MR spectroscopy in monitoring of post-operation irradiated patients. **1999**, 30, 154-61		34
485	Concurrent chemoradiation in the treatment of head and neck cancer. **1999**, 13, 719-42, vi-vii		21
484	Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. *Radiotherapy and Oncology*, **1999**, 50, 47-55	5.3	32
483	Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix. Results from a prospective controlled randomized trial. *Radiotherapy and Oncology*, **1999**, 50, 157-65	5.3	6
482	Altered fractionation: limited by mucosal reactions?. *Radiotherapy and Oncology*, **1999**, 50, 247-60	5.3	54
481	Changes in tumor hypoxia measured with a double hypoxic marker technique. *International Journal of Radiation Oncology Biology Physics*, **2000**, 48, 1529-38	4	76
480	Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. *International Journal of Radiation Oncology Biology Physics*, **2000**, 46, 459-66	4	188

479	Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. **2000**, 58, 1088-93; discussion 1093-5		201
478	Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma. *Acta Oncologica*, **2000**, 39, 199-205	3.2	8
477	Squamous cell carcinoma of the oropharynx--an analysis of treatment results in 289 consecutive patients. *Acta Oncologica*, **2000**, 39, 985-94	3.2	39
476	Hypopharyngeal squamous cell carcinoma--treatment results in 138 consecutively admitted patients. *Acta Oncologica*, **2000**, 39, 529-36	3.2	70
475	Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines. **2000**, 154, 547-55		34
474	Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. *Radiotherapy and Oncology*, **2000**, 56, 265-70	5.3	28
473	Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. *Radiotherapy and Oncology*, **2000**, 56, 175-9	5.3	36
472	A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. *Radiotherapy and Oncology*, **2000**, 57, 39-43	5.3	251
471	Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes. *Radiotherapy and Oncology*, **2000**, 57, 21-30	5.3	49
470	Head and neck cancer. **2001**, 345, 1890-900		1045
469	Does histologic grade have a role in the management of head and neck cancers?. **2001**, 19, 4107-16		55
468	Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. **2001**, 12, 1-6		25
467	99Tc(m) labelled HL91 versus computed tomography and biopsy for the visualization of tumour recurrence of squamous head and neck carcinoma. **2001**, 22, 269-75		18
466	In vivo evaluation of a novel antitumor prodrug, 1-(2Poxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 407-13	4	32
465	Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. *International Journal of Radiation Oncology Biology Physics*, **2001**, 50, 705-15	4	228
464	Quality assurance in a Radiation Oncology Unit: the Chart Round experience. **2001**, 45, 189-94		18
463	Potential molecular prognostic markers in head and neck squamous cell carcinomas. **2001**, 23, 147-59		119
462	Concomitant chemoradiation for head and neck cancer: saving lives or grays?. *Clinical Oncology*, **2001**, 13, 333-5	2.8	2

461	Sensitizers and protectors of radiation and chemotherapy. **2001**, 25, 334-411		28
460	The role of postradiotherapy neck dissection in supraglottic carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2001**, 50, 367-75	4	45
459	Translational Research--a new entity?. *Acta Oncologica*, **2001**, 40, 995-9	3.2	10
458	Squamous cell carcinoma of the nasopharynx--an analysis of treatment results in 149 consecutive patients. *Acta Oncologica*, **2001**, 40, 801-9	3.2	16
457	Impact of tumor hypoxia and anemia on radiation therapy outcomes. **2002**, 7, 492-508		275
456	Cancer of the larynx--treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. *Acta Oncologica*, **2002**, 41, 69-76	3.2	57
455	Hypoxia as a target for combined modality treatments. *European Journal of Cancer*, **2002**, 38, 240-57	7.5	159
454	Organ preservation trials for laryngeal cancer. **2002**, 35, 1035-54, vi		6
453	Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells. **2002**, 43, 161-6		13
452	Oral complications in the head and neck radiation patient. Introduction and scope of the problem. **2002**, 10, 36-9		62
451	Hypopharyngeal cancer: results of treatment based on radiation therapy and salvage surgery. **2002**, 112, 834-8		54
450	ARCON: experience in 215 patients with advanced head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2002**, 52, 769-78	4	161
449	Supraglottic carcinoma: patterns of failure and salvage treatment after curatively intended radiotherapy in 410 consecutive patients. *International Journal of Radiation Oncology Biology Physics*, **2002**, 53, 948-58	4	36
448	Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. **2003**, 179, 527-34		43
447	Combining bioreductive drugs and radiation for the treatment of solid tumors. *Seminars in Radiation Oncology*, **2003**, 13, 42-52	5.5	25
446	Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer: a national survey from DAHANCA. **2003**, 25, 711-6		73
445	How to overcome (and exploit) tumor hypoxia for targeted gene therapy. **2003**, 197, 312-25		55
444	Treatment of head and neck cancer with CHART and nimorazole: phase II study. *Radiotherapy and Oncology*, **2003**, 66, 65-70	5.3	25

443	Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. *Radiotherapy and Oncology*, **2003**, 66, 253-62	5.3	805
442	Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. *Radiotherapy and Oncology*, **2003**, 67, 3-15	5.3	235
441	The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. *Radiotherapy and Oncology*, **2003**, 68, 113-22	5.3	30
440	Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. *Radiotherapy and Oncology*, **2003**, 68, 171-4	5.3	15
439	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. **2003**, 362, 933-40		506
438	Laryngeal carcinoma--multivariate analysis of prognostic factors in 1252 consecutive patients treated with primary radiotherapy. *Acta Oncologica*, **2003**, 42, 771-8	3.2	34
437	A systematic overview of radiation therapy effects in head and neck cancer. *Acta Oncologica*, **2003**, 42, 443-61	3.2	92
436	Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology. **2003**, 3, 364-74		19
435	Recent advances in management of laryngeal cancer. **2004**, 36, 13-8		2
434	The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs. **2004**, 5, 2459-67		12
433	Preradiotherapy hemoglobin level but not microvessel density predicts locoregional control and survival in laryngeal cancer treated with primary radical radiotherapy. **2004**, 10, 7941-9		8
432	Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. **2004**, 9 Suppl 5, 31-40		271
431	Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck. **2004**, 112, 560-8		40
430	Targeted radiosensitisation by pegylated liposome-encapsulated 3P,5PO-dipalmitoyl 5-iodo-2Pdeoxyuridine in a head and neck cancer xenograft model. **2004**, 91, 366-73		13
429	Clinical studies of hypoxia modification in radiotherapy. *Seminars in Radiation Oncology*, **2004**, 14, 233-40	5.5	70
428	Strategies to overcome accelerated repopulation and hypoxia--what have we learned from clinical trials?. **2004**, 31, 802-8		28
427	Investigation of metabolic changes in irradiated rat brain tissue by means of 1H NMR in vitro relaxation study. **2004**, 25, 53-60		7
426	Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. **2004**, 180, 375-82		15

425	Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 750-7	4	118
424	Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2004**, 60, 1405-9	4	29
423	Influence of anaemia in patients with head and neck cancer receiving adjuvant postoperative radiotherapy in the Grampian region. *Clinical Oncology*, **2004**, 16, 63-70	2.8	18
422	Radiobiological rationale and patient selection for high-LET radiation in cancer therapy. *Radiotherapy and Oncology*, **2004**, 73 Suppl 2, S1-14	5.3	18
421	The role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck. **2004**, 13, 1-11		14
420	Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. *Acta Oncologica*, **2004**, 43, 396-403	3.2	118
419	Analyse de la littérature. **2004**, 8, 209-210		1
418	Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 119-28	4	42
417	Hypoxic cell turnover in different solid tumor lines. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 1157-68	4	76
416	Anemia, tumor hypoxemia, and the cancer patient. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 25-36	4	108
415	Hypoxia in head and neck cancer: how much, how important?. **2005**, 27, 622-38		141
414	Impact of anemia in patients with head and neck cancer treated with radiation therapy. **2005**, 6, 31-45		29
413	Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. **2005**, 46, 453-9		28
412	Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. *Acta Oncologica*, **2005**, 44, 168-73	3.2	12
411	Review of current treatment practices for carcinoma of the head and neck. **2005**, 6, 1143-55		13
410	Comorbidity as a major risk factor for mortality and complications in head and neck surgery. **2005**, 131, 27-32		151
409	Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: a meta-analysis. **2005**, 78, 777-82		7
408	Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. **2005**, 6, 757-64		244

407	Nimorazole may increase the effect of phenprocoumon. *Radiotherapy and Oncology*, **2005**, 74, 345	5.3	2
406	The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. *Radiotherapy and Oncology*, **2005**, 76, 135-42	5.3	24
405	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. *Radiotherapy and Oncology*, **2005**, 76, 206-12	5.3	36
404	Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiotherapy and Oncology*, **2005**, 77, 18-24	5.3	777
403	Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum. **2005**, 81, 937-44		17
402	Principles of Radiation Oncology. **2006**, 41-57		4
401	Tumour hypoxia - a characteristic feature with a complex molecular background. *Radiotherapy and Oncology*, **2006**, 81, 119-21	5.3	14
400	Analyse d'essais cliniques. **2006**, 10, 91-99		1
399	Hypoxia in biology and medicine: the legacy of L H Gray. **2006**, 79, 545-9		6
398	Design of hypoxia-targeting drugs as new cancer chemotherapeutics. **2006**, 29, 2335-42		51
397	Association between Anemia Arising during Therapy and Outcomes of Chemoradiation for Limited Small-cell Lung Cancer. **2006**, 1, 146-151		7
396	A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?. **2006**, 18, 253-7		20
395	Radiotherapy for head and neck cancer: latest developments and future perspectives. **2006**, 18, 240-6		15
394	Association between Anemia Arising during Therapy and Outcomes of Chemoradiation for Limited Small-cell Lung Cancer. **2006**, 1, 146-151		8
393	Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. *Clinical Oncology*, **2006**, 18, 139-44	2.8	20
392	Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 83-9	4	21
391	Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 562-72	4	56
390	Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study. *International Journal of Radiation Oncology Biology Physics*, **2006**, 65, 459-65	4	24

389	Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region. **2006**, 23, 1-15		13
388	Hypoxia in head and neck cancer. **2006**, 79, 791-8		68
387	Advanced imaging applied to radiotherapy planning in head and neck cancer: a clinical review. **2006**, 79, 554-61		40
386	Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. *Acta Oncologica*, **2007**, 46, 214-20	3.2	42
385	Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. **2007**, 12, 690-712		102
384	The rationale for and the current role of chemoradiotherapy. **2007**, 6, 11-19		6
383	Hyperfractionated accelerated radiotherapy in locally advanced head and neck cancers. **2007**, 30, 479-84		5
382	Tumor progression in waiting time for radiotherapy in head and neck cancer. *Radiotherapy and Oncology*, **2007**, 84, 5-10	5.3	190
381	Evidence-based radiation oncology in head and neck squamous cell carcinoma. *Radiotherapy and Oncology*, **2007**, 85, 156-70	5.3	127
380	Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. *Radiotherapy and Oncology*, **2007**, 83, 389-97	5.3	71
379	Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. *Radiotherapy and Oncology*, **2007**, 83, 383-8	5.3	52
378	Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. *Radiotherapy and Oncology*, **2007**, 85, 74-82	5.3	192
377	Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. **2007**, 8, 63-74		219
376	Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts. **2007**, 168, 65-71		7
375	Hypoxic radiosensitization: adored and ignored. **2007**, 25, 4066-74		486
374	Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. **2007**, 167, 127-45		145
373	11 Design of clinical trials in radiation oncology: saving lives, not grays. **2007**, 196-211		2
372	Targeting tumors with hypoxia-activated cytotoxins. **2007**, 12, 3483-501		47

371	8 The oxygen effect. **2007**, 138-157		5
370	Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. **2007**, 29, 591-604		83
369	The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. *Clinical Oncology*, **2007**, 19, 385-96	2.8	58
368	The importance of radiobiology to cancer therapy: current practice and future perspectives. *Clinical Oncology*, **2007**, 19, 367-9	2.8	1
367	Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 678-84	4	33
366	Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 504-11	4	50
365	Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002). *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 786-92	4	27
364	Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 1008-17	4	92
363	Changes in radiotherapeutic management of head and neck cancer: a 30-year perspective. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, S8-11	4	3
362	Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. **2007**, 32, 337-45		26
361	Current surgical treatment of squamous cell carcinoma of the head and neck. **2007**, 43, 213-23		48
360	High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. **2007**, 264, 1475-82		44
359	Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. **2008**, 35, 1803-11		77
358	Combining molecular therapeutics with radiotherapy for head and neck cancer. **2008**, 97, 708-11		9
357	High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. **2008**, 122, 857-63		36
356	Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 1108-14	4	60
355	Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 1202-12	4	69
354	Molecular aspects of tumour hypoxia. **2008**, 2, 41-53		114

353	New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. **2008**, 35, 236-50		36
352	The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists. *Acta Oncologica*, **2008**, 47, 150-1	3.2	3
351	The novel hypoxic cell radiosensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancer. **2008**, 272, 325-35		8
350	[The Oxygen effect: an old new target?]. **2008**, 12, 42-9		1
349	Positron emission tomography/computed tomography for target delineation in head and neck cancers. **2008**, 38, 141-8		43
348	Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. *Radiotherapy and Oncology*, **2008**, 87, 326-30	5.3	39
347	Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. *Radiotherapy and Oncology*, **2008**, 87, 331-8	5.3	14
346	Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. **2008**, 9, 288-96		279
345	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. **2008**, 9, 342-51		225
344	Treatment modelling: the influence of micro-environmental conditions. *Acta Oncologica*, **2008**, 47, 896-905	3.2	5
343	Bedeutung der Hypoxiebildgebung mit PET für die Bestrahlungsplanung. **2008**, 31, 33-36		1
342	Biology of Cancer. 3-22		
341	Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer. **2009**, 64, 885-92		10
340	Anemia during sequential induction chemotherapy and chemoradiation for head and neck cancer: the impact of blood transfusion on treatment outcome. *International Journal of Radiation Oncology Biology Physics*, **2009**, 73, 391-8	4	20
339	Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. *International Journal of Radiation Oncology Biology Physics*, **2009**, 74, 766-73	4	127
338	On the path to seeking novel radiosensitizers. *International Journal of Radiation Oncology Biology Physics*, **2009**, 73, 988-96	4	33
337	Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. **2009**, 27, 1992-8		482
336	Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. *Radiotherapy and Oncology*, **2009**, 92, 460-5	5.3	9

335	Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. *Radiotherapy and Oncology*, **2009**, 93, 539-44	5.3	61
334	Cancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspective. *Seminars in Cancer Biology*, **2010**, 20, 116-24	12.7	84
333	The tumor microenvironment in non-small-cell lung cancer. *Seminars in Radiation Oncology*, **2010**, 20, 156-63	5.5	90
332	Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. *Journal of Cellular and Molecular Medicine*, **2010**, 14, 18-29	5.6	116
331	Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. **2011**, 33, 375-82		54
330	Innovations in radiotherapy planning of head and neck cancers: role of PET. **2010**, 51, 66-76		68
329	Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. *Nature Reviews Clinical Oncology*, **2010**, 7, 616-8	19.4	
328	More lessons learned from the suffocation of hypoxia. **2010**, 28, 2941-3		21
327	Hypoxic tumors and their effect on immune cells and cancer therapy. *Methods in Molecular Biology*, **2010**, 651, 1-29	1.4	34
326	Safety and radiation-enhancing effect of sodium glycididazole in locoregionally advanced laryngeal cancers previously treated with platinum-containing chemotherapy regimens: A preliminary report. **2010**, 14, 59-64		12
325	HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. *Radiotherapy and Oncology*, **2010**, 94, 30-5	5.3	155
324	Single Arc Volumetric Modulated Arc Therapy of head and neck cancer. *Radiotherapy and Oncology*, **2010**, 95, 142-8	5.3	142
323	The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. *Radiotherapy and Oncology*, **2010**, 95, 371-80	5.3	131
322	PET-CT for response assessment and treatment adaptation in head and neck cancer. **2010**, 11, 661-9		93
321	Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. **2010**, 11, 553-60		90
320	Drug Penetration and Therapeutic Resistance. **2010**, 329-352		
319	Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials. *Acta Oncologica*, **2011**, 50, 1006-14	3.2	45
318	PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. *Nature Reviews Clinical Oncology*, **2011**, 8, 233-42	19.4	73

317	[Minutes of the 29th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Barcelona (Spain), 12-16 September 2010]. **2011**, 15, 154-60		
316	Interventions that induce modifications in the tumor microenvironment. **2011**, 15, 376-82		7
315	The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study. *Radiotherapy and Oncology*, **2011**, 98, 28-33	5.3	52
314	The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. *Radiotherapy and Oncology*, **2011**, 100, 49-55	5.3	154
313	Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. *Radiotherapy and Oncology*, **2011**, 100, 22-32	5.3	337
312	Perfusion estimated with rapid dynamic contrast-enhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 1176-83	4	58
311	Synergistic combination of hyperoxygenation and radiotherapy by repeated assessments of tumor pO2 with EPR oximetry. **2011**, 52, 568-74		13
310	Head and Neck Cancer Metastasis. 294-312		
309	Radiation Sensitizers. *Medical Radiology*, **2011**, 213-222	0.2	1
308	How can we overcome tumor hypoxia in radiation therapy?. **2011**, 52, 545-56		129
307	The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. **2011**, 7, 236-51		15
306	Strategies to improve radiotherapy with targeted drugs. **2011**, 11, 239-53		711
305	In regard to Brown et al. (Int J Radiat Oncol Biol Phys 2010;78:323-327). *International Journal of Radiation Oncology Biology Physics*, **2011**, 80, 1604-5; author reply 1605	4	1
304	Towards novel radiosensitizing agents: the role of cytosolic PLA2 in combined modality cancer therapy. **2011**, 3, 835-43		3
303	Combined hyperthermia and radiotherapy for the treatment of cancer. *Cancers*, **2011**, 3, 3799-823	6.6	68
302	Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. **2011**, 71, 5923-31		183
301	Reduction in waiting time for diagnosis and treatment of head and neck cancer - a fast track study. *Acta Oncologica*, **2011**, 50, 636-41	3.2	36
300	Cancer stem cells: targets and potential biomarkers for radiotherapy. **2011**, 17, 7224-9		79

299	Elusive goal of targeting tumor hypoxia for therapeutic gain. **2012**, 30, 1741-3		15
298	Radiobiology of Stereotactic Body Radiation Therapy/Stereotactic Ablative Radiotherapy. *Medical Radiology*, **2012**, 123-136	0.2	1
297	Hypoxia in head and neck squamous cell carcinoma. **2012**, 2012, 708974		17
296	Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. **2012**, 18, 301-7		42
295	Oncology ScanBiology. *International Journal of Radiation Oncology Biology Physics*, **2012**, 84, 1045-1047	4	2
294	Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. *Radiotherapy and Oncology*, **2012**, 102, 122-9	5.3	167
293	Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. *Radiotherapy and Oncology*, **2012**, 105, 21-8	5.3	229
292	Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. *Acta Oncologica*, **2012**, 51, 419-32	3.2	55
291	Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma--a prospective study. *Radiotherapy and Oncology*, **2012**, 103, 38-44	5.3	86
290	Hypoxia imaging markers and applications for radiation treatment planning. **2012**, 42, 343-52		26
289	The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer. **2012**, 42, 320-7		17
288	Individualization of cancer treatment from radiotherapy perspective. **2012**, 6, 211-21		54
287	Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors. **2012**, 7, 78		8
286	Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. *Frontiers in Pharmacology*, **2012**, 3, 94	5.6	63
285	Predicting recurrence after radiotherapy in head and neck cancer. *Seminars in Radiation Oncology*, **2012**, 22, 108-18	5.5	54
284	Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. *Seminars in Radiation Oncology*, **2012**, 22, 119-27	5.5	57
283	Dynamic changes in oxygenation of intracranial tumor and contralateral brain during tumor growth and carbogen breathing: a multisite EPR oximetry with implantable resonators. **2012**, 214, 22-8		29
282	Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. *Radiotherapy and Oncology*, **2013**, 108, 523-8	5.3	74

281	The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption. **2013**, 13, 106		8
280	In vitro hypoxic cytotoxicity and hypoxic radiosensitization. Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine. **2013**, 189, 246-54		10
279	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. *Acta Oncologica*, **2013**, 52, 1257-71	3.2	42
278	Prostate Cancer: Shifting from Morphology to Biology. **2013**,		1
277	Magnetic resonance imaging of tumor oxygenation and metabolic profile. *Acta Oncologica*, **2013**, 52, 1248-56	3.2	14
276	Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16 INK4a on treatment outcomes. **2013**, 123, 635-40		41
275	Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. *Radiotherapy and Oncology*, **2013**, 108, 489-94	5.3	42
274	Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. **2013**, 37, 301-12		1
273	Functional imaging for radiation treatment planning, response assessment, and adaptive therapy in head and neck cancer. **2013**, 33, 1909-29		62
272	Strategies for optimizing the response of cancer and normal tissues to radiation. **2013**, 12, 526-42		255
271	Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. *International Journal of Molecular Sciences*, **2013**, 14, 14800-32	6.3	28
270	Microenvironment and radiation therapy. **2013**, 2013, 685308		91
269	Carbogen gas and radiotherapy outcomes in prostate cancer. **2013**, 5, 25-34		5
268	Trial Watch: Anticancer radioimmunotherapy. **2013**, 2, e25595		75
267	[Minutes of the 33rd Congress of ESTRO held in Vienna (Austria), 4-8 April 2014]. **2014**, 101, 896-900		
266	Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. **2014**, 2014, 492061		33
265	Radiobiological modifiers in clinical radiation oncology: current reality and future potential. **2014**, 10, 2359-79		8
264	The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. **2014**, 25, 2101-2115		59

263	Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. *Radiotherapy and Oncology*, **2014**, 113, 310-6	5.3	121
262	The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. **2014**, 21, 1516-54		219
261	Potential role of hypoxia imaging using (18)F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapy. *Radiotherapy and Oncology*, **2014**, 113, 204-9	5.3	24
260	Molecular Determinants of Head and Neck Cancer. **2014**,		2
259	Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). *Acta Oncologica*, **2014**, 53, 654-61	3.2	24
258	Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. *Radiotherapy and Oncology*, **2014**, 110, 91-7	5.3	71
257	Formation of radical anions of radiosensitizers and related model compounds via electrospray ionization. **2014**, 365-366, 56-63		24
256	Hypoxia and Cancer. *Cancer Drug Discovery and Development*, **2014**,	0.3	4
255	Tumor microenvironment and cellular stress: signaling, metabolism, imaging, and therapeutic targets. Preface. *Advances in Experimental Medicine and Biology*, **2014**, 772, v-viii	3.6	22
254	Insights into the relationship between HPV/p16 status, hypoxia imaging and treatment outcomes in head and neck cancer. *Journal of Medical Imaging and Radiation Oncology*, **2014**, 58, 98-100	1.7	
253	Tumor Hypoxia. **2014**, 205-222		
252	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. **2014**, 1, 75-86		65
251	Prognostic significance of blood transfusion and anaemia on survival in stage IIIA/B/C and IVA oesophageal cancers treated with chemoradiotherapy. **2014**, 3, 167-177		2
250	Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy. **2014**, 9, 87		40
249	NIMRAD - a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. *Clinical Oncology*, **2014**, 26, 344-7	2.8	42
248	Molecular imaging of tumor hypoxia with positron emission tomography. **2014**, 181, 335-49		34
247	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. **2014**, 390-405		
246	A rapid and sensitive determination of hypoxic radiosensitizer agent nimorazole in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. **2015**, 29, 1575-80		4

245	Radiation enhancing effects of sanazole and gemcitabine in hypoxic breast and cervical cancer cells in vitro. **2015**, 19, 236-40		1
244	From the Point of View of Tumor Biology. **2015**, 64, 67-77		
243	Predictive value of (18)F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: a preclinical study. *Radiotherapy and Oncology*, **2015**, 114, 189-94	5.3	20
242	Photoelectron Spectra and Electronic Structures of the Radiosensitizer Nimorazole and Related Compounds. **2015**, 119, 9986-95		14
241	Optimizing hypoxia detection and treatment strategies. **2015**, 45, 163-76		30
240	Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial. *Clinical Oncology*, **2015**, 27, 168-75	2.8	8
239	Drug radiotherapy combinations: review of previous failures and reasons for future optimism. **2015**, 41, 105-13		56
238	The clinical significance of hypoxia in human cancers. **2015**, 45, 110-21		133
237	IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. *Radiotherapy and Oncology*, **2015**, 116, 15-20	5.3	31
236	The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. *Radiotherapy and Oncology*, **2015**, 117, 91-8	5.3	44
235	The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. **2015**, 15, 409-25		1022
234	Anticancer Drugs Acting via Radical Species: Radiotherapy and Photodynamic Therapy of Cancer. **2015**, 133-195		6
233	Reactions in Nitroimidazole and Methylnitroimidazole Triggered by Low-Energy (0-8 eV) Electrons. **2015**, 119, 6668-75		16
232	Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. *Acta Oncologica*, **2015**, 54, 1001-7	3.2	67
231	Modulation of the tumor vasculature and oxygenation to improve therapy. **2015**, 153, 107-24		70
230	Personalized radiotherapy: concepts, biomarkers and trial design. **2015**, 88, 20150009		20
229	Decomposition of nitroimidazole ions: experiment and theory. **2015**, 17, 12598-607		24
228	Emerging drugs for head and neck cancer. **2015**, 20, 313-29		23

227	Hypoxia and Predicting Radiation Response. *Seminars in Radiation Oncology*, **2015**, 25, 260-72	5.5	54
226	Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand. **2015**, 21, 1995-2000		32
225	[TH-302: a new hypoxia-activated cytostatic agent in pancreatic cancer treatment]. **2015**, 191, 819-20		
224	Epidermal growth factor receptor imaging in human head and neck cancer xenografts. *Acta Oncologica*, **2015**, 54, 1263-7	3.2	6
223	Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy. *Acta Oncologica*, **2015**, 54, 1385-92	3.2	8
222	Multinational study exploring patientsPperceptions of side-effects induced by chemo-radiotherapy. *Radiotherapy and Oncology*, **2015**, 117, 333-7	5.3	16
221	Gene Expression Signatures as Biomarkers of Tumour Hypoxia. *Clinical Oncology*, **2015**, 27, 547-60	2.8	74
220	Human Papillomavirus-Negative Pharyngeal Cancer. **2015**, 33, 3251-61		40
219	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. **2015**, 30, 689-721		79
218	Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. **2016**, 38 Suppl 1, E1102-9		31
217	Pharmacokinetic modeling of a novel hypoxia PET tracer [F]HX4 in patients with non-small cell lung cancer. **2016**, 3, 30		9
216	Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. *Radiotherapy and Oncology*, **2016**, 118, 257-66	5.3	25
215	The impact of hypoxia and its modification of the outcome of radiotherapy. **2016**, 57 Suppl 1, i90-i98		172
214	Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. *Acta Oncologica*, **2016**, 55, 1091-1098	3.2	48
213	How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. **2016**, 46, 1-8		29
212	Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial. *Radiotherapy and Oncology*, **2016**, 120, 383-389	5.3	17
211	Safety of drug treatments for head and neck cancer. **2016**, 15, 1527-1539		3
210	Hypoxia: A Double-Edged Sword in Cancer Therapy. **2016**, 34, 536-545		87

209	The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. **2016**, 7, 12308		122
208	Management of Oropharyngeal Cancer in the HPV Era. **2016**, 23, 197-207		6
207	Prediction of critical weight loss during radiation treatment in head and neck cancer patients is dependent on BMI. **2016**, 24, 2101-2109		29
206	TH-302 – ein neues unter Hypoxie aktiviertes Zytostatikum beim Pankreaskarzinom. **2016**, 19, 25-26		
205	Molecular Radio-Oncology. **2016**,		1
204	Emerging targets for radioprotection and radiosensitization in radiotherapy. **2016**, 37, 11589-11609		22
203	Tumor Microenvironment. *Advances in Experimental Medicine and Biology*, **2016**,	3.6	2
202	Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy. **2016**, 198, 143-61		2
201	Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers. *Advances in Experimental Medicine and Biology*, **2016**, 899, 269-90	3.6	2
200	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase´III trials (ARO´95-06, SAKK´10/94). **2016**, 192, 552-60		13
199	Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?. **2016**, 16, 751-8		29
198	Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. **2016**, 103, 86-98		12
197	Radiation oncology in the era of precision medicine. **2016**, 16, 234-49		438
196	Elective Nodal Irradiation and Patterns of Failure in Head and Neck Cancer After Primary Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 775-82	4	22
195	Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis. **2016**, 99, 123-8		5
194	Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy. **2016**, 121, 229-37		5
193	Dose-Response Modifiers in Radiation Therapy. **2016**, 51-62.e3		3
192	Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. *Clinical Oncology*, **2016**, 28, 50-61	2.8	14

191	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. **2017**, 187, 147-160		33
190	Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients. **2017**, 2, 46-52		5
189	Mitochondrion-Anchoring Photosensitizer with Aggregation-Induced Emission Characteristics Synergistically Boosts the Radiosensitivity of Cancer Cells to Ionizing Radiation. **2017**, 29, 1606167		173
188	Integration of PET/MR Hybrid Imaging into Radiation Therapy Treatment. **2017**, 25, 377-430		6
187	The Radiation Stress Response: Of the People, By the People and For the People. **2017**, 187, 129-146		1
186	Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. *Radiotherapy and Oncology*, **2017**, 123, 424-430	5.3	13
185	Radiation Biology for Radiation Oncologists. **2017**, 15-61		1
184	Facile Preparation and Radiotherapy Application of an Amphiphilic Block Copolymer Radiosensitizer. **2017**, 6, 556-560		8
183	So long, Farewell, Au revoir, Auf Weidersehen. In regard to Overgaard (Radiother Oncol. 2016 Dec; 121(3):345-347). *Radiotherapy and Oncology*, **2017**, 122, 486	5.3	
182	Nanoparticles for radiooncology: Mission, vision, challenges. **2017**, 120, 155-184		73
181	Impact of hypoxia in head and neck cancer radiotherapy. **2017**, 5, 497-505		3
180	Progressive resistance training in head and neck cancer patients undergoing concomitant chemoradiotherapy. **2017**, 2, 295-306		15
179	Nitroimidazolic radiosensitizers investigated by electrospray ionization time-of-flight mass spectrometry and density functional theory. **2017**, 7, 45211-45221		8
178	Therapeutic options to overcome tumor hypoxia in radiation oncology. **2017**, 5, 455-464		4
177	Fragmentation patterns of 4(5)-nitroimidazole and 1-methyl-5-nitroimidazole-The effect of the methylation. **2017**, 52, 770-776		8
176	How does methylation suppress the electron-induced decomposition of 1-methyl-nitroimidazoles?. **2017**, 147, 164310		13
175	Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 1183-1196	4	81
174	Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial. **2017**, 17, 400		12

173	Biomarker driven treatment of head and neck squamous cell cancer. **2017**, 2, 6		14
172	Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole and. **2018**, 15, 1993-1998		
171	Discovery of the Hypoxia-Activated Prodrug SN30000. **2017**, 58-94		4
170	Improving radiotherapy in cancer treatment: Promises and challenges. *Oncotarget*, **2017**, 8, 62742-62758	5.3	103
169	Targeting tumour hypoxia: shifting focus from oxygen supply to demand. **2019**, 92, 20170843		11
168	DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. *Radiotherapy and Oncology*, **2018**, 127, 12-19	5.3	16
167	Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes. **2019**, 92, 20170915		20
166	Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides. **2018**, 61, 1241-1254		37
165	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. **2018**, 31, 182-189		67
164	Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. **2018**, 47, 484-491		8
163	Tumor oxygenation and cancer therapy-then and now. **2019**, 92, 20170955		25
162	HPV, hypoxia and radiation response in head and neck cancer. **2019**, 92, 20180047		24
161	Cancer Radiosensitizers. **2018**, 39, 24-48		228
160	HPV Assessment in Oropharynx Cancer: What is the Gold Standard?. **2018**, 119-147		1
159	High-energy collision-induced dissociation of radiosensitizer anions: Nimorazole and metronidazole. **2018**, 431, 1-7		2
158	Correlation of hypoxia status with radiosensitizing effects of sodium glycididazole: A preclinical study. **2018**, 15, 6481-6488		3
157	Machine Learning and Radiogenomics: Lessons Learned and Future Directions. *Frontiers in Oncology* , **2018**, 8, 228	5.3	41
156	Clinical trials targeting hypoxia. **2019**, 92, 20170966		17

155	Hypoxia imaging with F-FAZA PET/CT predicts radiotherapy response in esophageal adenocarcinoma xenografts. **2018**, 13, 39		17
154	Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. **2018**, 45, 2201-2217		32
153	Multidirectional Efficacy of Biologically Active Nitro Compounds Included in Medicines. **2018**, 11,		42
152	Imageable Biomarkers for Radiotherapy Response. **2018**, 11-24		
151	Subglottic squamous cell carcinoma in Denmark 1971-2015 - a national population-based cohort study from DAHANCA, the Danish Head and Neck Cancer group. *Acta Oncologica*, **2019**, 58, 1509-1513	3.2	1
150	Reactions in the Radiosensitizer Misonidazole Induced by Low-Energy (0-10 eV) Electrons. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	7
149	Approaches to combat hypoxia in cancer therapy and the potential for in silico models in their evaluation. **2019**, 64, 145-156		8
148	Tumour Hypoxia. *Clinical Oncology*, **2019**, 31, 595-599	2.8	7
147	Ro 90-7501 Is a Novel Radiosensitizer for Cervical Cancer Cells that Inhibits ATM Phosphorylation. **2019**, 39, 4805-4810		4
146	Characterization of Micro- and Nanoscale LuPO4:Pr3+,Nd3+ with Strong UV-C Emission to Reduce X-Ray Doses in Radiation Therapy. **2019**, 36, 1900280		10
145	Decomposition of protonated ronidazole studied by low-energy and high-energy collision-induced dissociation and density functional theory. **2019**, 151, 164306		1
144	DAHANCA 9 - a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). *Acta Oncologica*, **2019**, 58, 1502-1505	3.2	5
143	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. *Frontiers in Oncology*, **2019**, 9, 815	5.3	31
142	A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. *Acta Oncologica*, **2019**, 58, 1495-1501	3.2	14
141	Hypoxia-targeted drug delivery. **2019**, 48, 771-813		210
140	Hypoxia Mediates Tumor Malignancy and Therapy Resistance. *Advances in Experimental Medicine and Biology*, **2019**, 1136, 1-18	3.6	40
139	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. **2019**, 25, 5315-5328		54
138	Selective Bond Excision in Nitroimidazoles by Electron Transfer Experiments. **2019**, 123, 4068-4073		7

137	Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives. *Cancers*, **2019**, 11,	6.6	17
136	Controlling NO Production Upon Valence Ionization of Nitroimidazoles. **2019**, 123, 3074-3079		6
135	Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro. **2019**, 30, 264001		11
134	Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs. *Clinical Oncology*, **2019**, 31, 290-302	2.8	15
133	In vivo drug screening method of radiosensitizers using tumor-bearing chick embryo. **2019**, 46, 113-127		0
132	Electron Transfer Induced Decomposition in Potassium-Nitroimidazoles Collisions: An Experimental and Theoretical Work. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	5
131	Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 1908-1916	5.6	6
130	Basics of Radiation Therapy. **2020**, 431-460.e3		0
129	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. *Seminars in Cancer Biology*, **2020**, 65, 140-154	12.7	30
128	Practical Radiation Oncology. **2020**,		2
127	Determinants of Sensitivity to Radiotherapy in Endometrial Cancer. *Cancers*, **2020**, 12,	6.6	9
126	The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology. **2020**, 7, 598338		2
125	5-Nitro-2,4-Dichloropyrimidine as an Universal Model for Low-Energy Electron Processes Relevant for Radiosensitization. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
124	The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. *Radiotherapy and Oncology*, **2020**, 151, 149-151	5.3	20
123	The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review. *Frontiers in Oncology*, **2020**, 10, 1402	5.3	4
122	A new prognostic hypoxia biomarker consisting of imaging and gene-based data. **2020**, 58, 102901		
121	Targeting Tumor Hypoxia. *Cancer Drug Discovery and Development*, **2020**, 265-299	0.3	
120	Molecular Targeted Radiosensitizers. *Cancer Drug Discovery and Development*, **2020**,	0.3	

119	Inside the hypoxic tumour: reprogramming of the DDR and radioresistance. **2020**, 6, 77		29
118	2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche. **2020**, 3, 450		14
117	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. *Cancers*, **2020**, 12,	6.6	7
116	DCE-MRI Quantitative Parameters as Predictors of Treatment Response in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Underwent CCRT. *Frontiers in Oncology*, **2020**, 10, 585738	5.3	3
115	Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. **2020**, 26, 4723-4736		12
114	Perspective: Do Fasting, Caloric Restriction, and Diets Increase Sensitivity to Radiotherapy? A Literature Review. **2020**, 11, 1089-1101		6
113	Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. **2020**, 50, 562-583		13
112	Four decades with ESTRO. *Radiotherapy and Oncology*, **2020**, 142, 1-5	5.3	2
111	Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas. *Journal of Experimental and Clinical Cancer Research*, **2020**, 39, 129	12.8	11
110	Fragmentation Patterns of Radiosensitizers Metronidazole and Nimorazole upon Valence Ionization. **2020**, 124, 5555-5562		5
109	Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue-based research. **2020**, 250, 593-611		15
108	From Anemia to Erythropoietin Resistance in Head and Neck Squamous Cell Carcinoma Treatment: A Carousel Driven by Hypoxia. **2020**, 13, 841-851		5
107	Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways. *Frontiers in Oncology*, **2020**, 10, 562	5.3	54
106	DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity. *Radiotherapy and Oncology*, **2020**, 148, 65-72	5.3	9
105	Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect. **2021**, 29, 115889		0
104	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting. **2021**, 59-81		
103	Does the combination of hyperthermia with low LET (linear energy transfer) radiation induce anti-tumor effects equivalent to those seen with high LET radiation alone?. **2021**, 38, 105-110		1
102	Electron-Induced Decomposition of Uracil-5-yl (,-dimethylsulfamate): Role of Methylation in Molecular Stability. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	0

101	Application of Radiosensitizers in Cancer Radiotherapy. **2021**, 16, 1083-1102		37
100	Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer. **2021**, 14, 101017		12
99	Ring-Selective Fragmentation in the Tirapazamine Molecule upon Low-Energy Electron Attachment. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
98	Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database. **2021**, 125, 458-464		1
97	Synthetic Approaches for N-Labeled Hyperpolarized Heterocyclic Molecular Imaging Agents for N NMR Signal Amplification by Reversible Exchange in Microtesla Magnetic Fields. **2021**, 27, 9727-9736		3
96	Identification of proteins and cellular pathways targeted by 2-nitroimidazole hypoxic cytotoxins. *Redox Biology*, **2021**, 41, 101905	11.3	0
95	Lost in application: Measuring hypoxia for radiotherapy optimisation. *European Journal of Cancer*, **2021**, 148, 260-276	7.5	9
94	A Mesoscale Computational Model for Microvascular Oxygen Transfer. *Annals of Biomedical Engineering*, **2021**, 1	4.7	2
93	Interfering with Tumor Hypoxia for Radiotherapy Optimization. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 197	12.8	14
92	Hypoxia and its Modification in Bladder Cancer: Current and Future Perspectives. *Clinical Oncology*, **2021**, 33, 376-390	2.8	1
91	Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 1222-1233	4	4
90	Therapeutic targeting of the hypoxic tumour microenvironment. *Nature Reviews Clinical Oncology*, **2021**, 18, 751-772	19.4	32
89	Engineering Tools for Regulating Hypoxia in Tumour Models. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 7581-7592	5.6	3
88	Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models. *Physics and Imaging in Radiation Oncology*, **2021**, 19, 145-150	3.1	2
87	Targeted and Non-Targeted Mechanisms for Killing Hypoxic Tumour Cells-Are There New Avenues for Treatment?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	
86	Distant metastases in squamous cell carcinoma of the pharynx and larynx: a population-based DAHANCA study. *Acta Oncologica*, **2021**, 60, 1472-1480	3.2	
85	[Radiation Oncology - Recent Status]. *Praxis*, **2021**, 110, 733-742	0.1	
84	Hypoxic gene expression is a prognostic factor for disease free survival in a cohort of locally advanced squamous cell cancer of the uterine cervix. *Acta Oncologica*, **2021**, 1-7	3.2	1

83	Impact of hypoxia on cervical cancer outcomes. *International Journal of Gynecological Cancer*, **2021**, 31, 1459-1470	3.5	2
82	Therapeutic Modification of Hypoxia. *Clinical Oncology*, **2021**, 33, e492-e509	2.8	2
81	Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology. *Seminars in Radiation Oncology*, **2021**, 31, 371-388	5.5	2
80	[The role of chemoradiotherapy in curative treatment of head and neck cancer]. *Laryngo- Rhino-Otologie*, **2021**,	0.8	0
79	Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. **2021**, 119-137		
78	Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter. *Cancers*, **2021**, 13,	6.6	25
77	Radiosensitizers and Radioprotective Agents. **2003**, 151-214		6
76	Impact on Radiotherapy. 353-376		1
75	Larynxkarzinom. **2006**, 3397-3420		0
74	Hypoxia-directed drug strategies to target the tumor microenvironment. *Advances in Experimental Medicine and Biology*, **2014**, 772, 111-45	3.6	17
73	Hypoxia and Radiation Therapy. *Cancer Drug Discovery and Development*, **2014**, 265-281	0.3	1
72	Imaging angiogenesis. *Methods in Molecular Biology*, **2009**, 467, 25-51	1.4	22
71	Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients. **2017**, 77-96		1
70	Role of Signaling Pathway Modification. *Medical Radiology*, **2003**, 157-178	0.2	1
69	Principles of Radiation Oncology. **2003**, 9-17		4
68	Radiosensitizers and Radioprotectors. **2020**, 179-183		2
67	Chemical Modifiers of Radiation Response. **2010**, 55-68		7
66	Dose-Response Modifiers in Radiation Therapy. **2012**, 53-64		1

65	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. *JCI Insight*, **2018**, 3,	9.9	31
64	Characterizing Heterogeneity within Head and Neck Lesions Using Cluster Analysis of Multi-Parametric MRI Data. *PLoS ONE*, **2015**, 10, e0138545	3.7	6
63	Enhanced radiosensitizing by sodium glycididazole in a recurrent esophageal carcinoma tumor model. *Oncotarget*, **2017**, 8, 63871-63880	3.3	3
62	Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment.. **2020**, 3, 775-790		2
61	Positron emission tomography to assess hypoxia and perfusion in lung cancer. *World Journal of Clinical Oncology*, **2014**, 5, 824-44	2.5	8
60	A Review of the Role of Hypoxia in Radioresistance in Cancer Therapy. *Medical Science Monitor*, **2021**, 27, e934116	3.2	0
59	Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. *Frontiers in Oncology*, **2021**, 11, 749496	5.3	0
58	Basic Concepts Underlying Radiation Therapy. **2005**, 70-74		
57	Update on clinical radiobiology. *Biomedical Imaging and Intervention Journal*, **2006**, 2, e22		0
56	Treatment Options for Laryngeal and Hypopharyngeal Cancer. **2009**, 183-195		
55	Cancer of the Oropharynx. **2010**, 546-587		
54	Radiotherapy for Head and Neck Cancer. **2010**, 1030-1050		
53	Malignant Neoplasms of the Oropharynx. **2010**, 1358-1374		
52	Prediction of Radiation Response. **2010**, 69-81		
51	Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment. **2011**, 169-178		
50	Translational Research in Head and Neck Oncology. **2011**, 179-189		
49	Tumour characteristics, development and response to radiation. **2012**, 89-105		
48	Counteracting Hypoxia in Radio-Resistant Metastatic Lesions. **2013**, 255-269		

47	Basics of Radiation Therapy. **2014**, 393-422.e3		1
46	Hypoxia and Radioresistance in Head and Neck Cancer. **2014**, 283-302		
45	Principles of Radiation Oncology. **1999**, 13-35		
44	Hypoxia in Head and Neck Cancers: Clinical Relevance and Treatment. **2016**, 229-242		
43	Translational Research in Head and Neck Oncology. **2016**, 215-227		
42	Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Symptomatic Uterine Fibroids and Normal Uterus: A Feasibility Study. *Iranian Journal of Radiology*, **2016**, inpress,	1.4	
41	Hypoxia in Head and Neck Cancer. **2017**, 59-95		
40	Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer. *Current Cancer Research*, **2018**, 327-352	0.2	
39	The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. *Current Cancer Research* , **2018**, 397-438	0.2	
38	Targeting Hypoxia: Revival of Old Remedies. *Biomolecules*, **2021**, 11,	5.9	2
37	Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation. **2006**, 67-91		
36	The Role of Tumor Hypoxia in Head and Neck Cancer Radiotherapy. **2005**, 145-163		1
35	Oxidative Stress and Hypoxia in Cancer: Implications for Radiation Therapy. **2021**, 1-26		
34	Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology. *Seminars in Radiation Oncology*, **2022**, 32, 42-53	5.5	1
33	Hypoxia and Its Influence on Radiotherapy Response of HPV-Positive and HPV-Negative Head and Neck Cancer. *Cancers*, **2021**, 13,	6.6	5
32	STABILITY INDICATING OPTIMIZED RP-HPLC METHOD APPLYING QBD PRINCIPLES FOR QUANTITATIVE ESTIMATION OF NIMORAZOLE. *Indian Drugs*, **2016**, 53, 41-46	0.2	
31	Oxidative Stress and Hypoxia in Cancer: Implications for Radiation Therapy. **2022**, 2023-2048		
30	Targeting OXPHOS and the electronic transport chain in cancer; molecular and therapeutic implications.. *Seminars in Cancer Biology*, **2022**,	12.7	2

29	Transfusion thresholds for guiding red blood cell transfusion.. *The Cochrane Library*, **2021**, 12, CD002042	5.2	4
28	Cellular mechanism of action of 2-nitroimidazoles as hypoxia-selective therapeutic agents.. *Redox Biology*, **2022**, 52, 102300	11.3	2
27	Kurative Radiochemotherapie von Kopf-Hals-Tumoren. *Tumor Diagnostik Und Therapie*, **2022**, 43, 120-132	0.1	
26	Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.. *Radiotherapy and Oncology*, **2022**,	5.3	
25	Radiosensitization of PC3 Prostate Cancer Cells by 5-Thiocyanato-2Pdeoxyuridine.. *Cancers*, **2022**, 14,	6.6	0
24	Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.. *Journal of Medical Imaging and Radiation Oncology*, **2022**,	1.7	
23	Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches. *Journal of Personalized Medicine*, **2022**, 12, 854	3.6	1
22	Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn offOn Probes for Hypoxia Imaging. *Cancers*, **2022**, 14, 2686	6.6	0
21	Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients with Head and Neck Region Tumours. *Biomedicines*, **2022**, 10, 1484	4.8	
20	The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. *Frontiers in Pharmacology*, 13,	5.6	1
19	Hyperbaric Oxygen Therapy as a Complementary Treatment in GlioblastomaA Scoping Review. *Frontiers in Neurology*, 13,	4.1	
18	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. *Biomedicines*, **2022**, 10, 1763	4.8	0
17	Interactions of radiation therapy with common and innovative systemic treatments: Antidiabetic treatments, antihypertensives, lipid-lowering medications, immunosuppressive medications and other radiosensitizing methods. **2022**,		0
16	Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation. **2022**, 133, 106054		0
15	Darbepoietin Alfa Potentiates the Efficacy of Radiation Therapy in Mice with Corrected or Uncorrected Anemia. **2005**, 65, 284-290		3
14	Overcoming the Impact of Hypoxia in Driving Radiotherapy Resistance in Head and Neck Squamous Cell Carcinoma. **2022**, 14, 4130		0
13	Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art. **2022**, 23, 10211		0
12	The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma. **2022**, 14, 4694		0

11	Radiosensitizers in Radiation-Induced Cancer Therapy. **2022**, 27-57	0
10	Exploring the role of neutrophil-to-lymphocyte ratio and blood chemistry in head and neck adenoid cystic carcinomas treated with carbon ion radiotherapy. **2022**,	0
9	Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials.	0
8	Anti-hypoxic Agents for Improving Head and Neck Cancer Therapy. **2022**,	0
7	Outcomes Stratification of Head and Neck Cancer Using Pre- and Posttreatment DNA Methylation From Peripheral Blood. **2022**,	0
6	The Effect of Single Bout and Prolonged Aerobic Exercise on Tumour Hypoxia in Mice.	0
5	Influence of 2-Nitroimidazoles in the Response of FaDu Cells to Ionizing Radiation and Hypoxia/Reoxygenation Stress. **2023**, 12, 389	0
4	Treatment Intensification in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: What Are the Options and for Whom?. **2023**, 129-164	0
3	In Vitro Characterization of the Bacteria-derived Hypoxia- Selective Cytotoxin Be-43547.	0
2	Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.	0
1	Optimized Carbohydrate-Based Nanogel Formulation to Sensitize Hypoxic Tumors.	0